Evolution of Diploid Progenitor Lung Cell Applications: From Optimized Biotechnological Substrates to Potential Active Pharmaceutical Ingredients in Respiratory Tract Regenerative Medicine.

Details

Ressource 1Request a copy Sous embargo indéterminé.
State: Public
Version: author
License: CC BY 4.0
Serval ID
serval:BIB_3A4B102DBA12
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Evolution of Diploid Progenitor Lung Cell Applications: From Optimized Biotechnological Substrates to Potential Active Pharmaceutical Ingredients in Respiratory Tract Regenerative Medicine.
Journal
Cells
Author(s)
Laurent A., Abdel-Sayed P., Hirt-Burri N., Scaletta C., Michetti M., de Buys Roessingh A., Raffoul W., Applegate L.A.
ISSN
2073-4409 (Electronic)
ISSN-L
2073-4409
Publication state
Published
Issued date
24/09/2021
Peer-reviewed
Oui
Volume
10
Number
10
Pages
2526
Language
english
Notes
Publication types: Historical Article ; Journal Article ; Review
Publication Status: epublish
Abstract
The objective of this review is to describe the evolution of lung tissue-derived diploid progenitor cell applications, ranging from historical biotechnological substrate functions for vaccine production and testing to current investigations around potential therapeutic use in respiratory tract regenerative medicine. Such cell types (e.g., MRC-5 or WI-38 sources) were extensively studied since the 1960s and have been continuously used over five decades as safe and sustainable industrial vaccine substrates. Recent research and development efforts around diploid progenitor lung cells (e.g., FE002-Lu or Walvax-2 sources) consist in qualification for potential use as optimal and renewed vaccine production substrates and, alternatively, for potential therapeutic applications in respiratory tract regenerative medicine. Potentially effective, safe, and sustainable cell therapy approaches for the management of inflammatory lung diseases or affections and related symptoms (e.g., COVID-19 patients and burn patient severe inhalation syndrome) using local homologous allogeneic cell-based or cell-derived product administrations are considered. Overall, lung tissue-derived progenitor cells isolated and produced under good manufacturing practices (GMP) may be used with high versatility. They can either act as key industrial platforms optimally conforming to specific pharmacopoeial requirements or as active pharmaceutical ingredients (API) for potentially effective promotion of lung tissue repair or regeneration.
Keywords
Animals, Biological Specimen Banks, Biotechnology/methods, COVID-19 Vaccines, Cell Line, Cell- and Tissue-Based Therapy, Diploidy, History, 20th Century, History, 21st Century, Humans, Lung/cytology, Lung/physiology, Regeneration, Regenerative Medicine/history, Regenerative Medicine/methods, Respiratory Tract Infections/therapy, SARS-CoV-2, Stem Cell Transplantation, Stem Cells/cytology, Transplantation, Homologous, COVID-19, MRC-5 cells, active pharmaceutical ingredient, cell banking, cell therapy, diploid progenitor cells, inflammatory lung disease, lung cells, regenerative medicine, vaccine substrate
Pubmed
Web of science
Open Access
Yes
Create date
30/09/2021 13:14
Last modification date
20/11/2021 6:34
Usage data